Hence, combination therapy or improvement of chemical structures to enhance the OAT10 inhibitory activity of such urate-lowering drugs may be a potential strategy to provide a more effective anti-gout (urate-lowering) therapy. This evidence concerns the gene SLC22A13 and gout.